Ipsen S.A. (VIE:IPN)

Market Cap	12.98B +53.4%
Revenue (ttm)	3.93B +9.9%
Net Income	443.50M +28.2%
EPS	5.32 +28.2%
Shares Out	n/a
PE Ratio	29.27
Forward PE	12.02
Dividend	1.60 (0.99%)
Ex-Dividend Date	Jun 3, 2026

Volume	n/a
Open	157.30
Previous Close	159.70
Day's Range	155.30 - 157.30
52-Week Range	100.40 - 173.10
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i...

• Industry: Pharmaceutical Preparations
• Founded: 1929
• Employees: 5,535
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: IPN

Financial Performance

In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.